Market Overview

Valeant's Asset Sale To L'Oreal Explained

Share:
Valeant's Asset Sale To L'Oreal Explained

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced an agreement to sell its CeraVe, AcneFree and AMBI Skincare brands to L'Oreal SA (ADR) (OTC: LRLCY) for $1.3 billion.

According to Gadfly's Andrea Felsted, the $1.3 billion price tag on the deal is worth it for the France-based consumer goods empire.

Felsted continued that while makeup products have seen a tremendous surge in demand as of late, dubbed by some the "selfie generation," demand for skincare products that solve problems have been quietly rising behind the scenes.

It Just Makes Sense

As such, L'Oreal's acquisition is expected to bolster one of its fastest-growing segments, active cosmetics. Specifically, the new additions to L'Oreal's portfolio will boost the company's presence in the United States.

L'Oreal is expecting the three brands to help double the revenue of its cosmetics division. In fact, organic sales for L'Oreal in North America has been rising at a faster rate than Western Europe, it makes sense for the company to bolster its line up.

Felsted also pointed out another reason for L'Oreal to justify its acquisition: If it doesn't, then its rivals may. For example, Unilever plc (ADR) (NYSE: UL) has been active in acquiring premium personal care lines, while Nestle SA (ADR) (OTC: NSRGY) has been investing in its own health science business, which includes a skin health segment.

Finally, L'Oreal can easily afford to buy Valeant's segments given its 96 billion euro market capitalization and 3 billion annual free cash flow.

Image Credit: By Edelseider - Own work, CC BY-SA 4.0, Wikimedia Commons

Posted-In: Andrea Felsted Gadfly LOreal ValeantNews Asset Sales Media Trading Ideas Best of Benzinga

 

Related Articles (LRLCY + NSRGY)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com